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ABSTRACT
Background: Burning mouth syndrome (BMS) is a chronic idiopathic oral 
dysaesthesia that presents as a burning sensation in the oral cavity usually 
without any specific oral lesions or laboratory findings. Burning sensations may 
appear on the buccal mucosa, hard and soft palate, tongue and lips. BMS appears 
to be more prevalent in postmenopausal women. The term menopause is often 
used for a condition in which the permanent cessation of the primary function of 
the ovaries in humans that occurs especially in middle-aged women. Available 
evidence suggested that BMS is a multifactorial disorder with physiological basis. 
Pathophysiology of BMS remains unclear. The etiopathogenesis in most patients 
who complain of burning sensations have interactions with several factors such as 
local, systemic, and/ or psychogenic factors. The aim of this literature review was to 
assess and evaluate the management of BMS comprehensively. 
Discussion: The therapy of BMS including hormone replacement therapy, 
systemically therapy, such as antidepressants, clonazepam and topical medication 
(clonidine and capsaicin) and reassurance as the stress management. 
Conclusion: Proper management of the BMS involves the combination of 
pharmacologic treatment and psychotherapy, as well as reassurance is an important 
thing
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Burning mouth syndrome (BMS) is an id-
iopathic burning discomfort or pain affecting 
people with clinically normal mucosa, defined 
as a spontaneous syndrome of burning sen-
sation, discomfort, pain, irritation or rawness 
of the tongue, lips or oral cavity, often without 
organic cause that present a difficult diagnosis 
for many clinicians.1,2,3
Prevalence rate between 0,7-2,6% reported 
from National Institutes of Health (NIH) survey 
estimating close to 1 million burning mouth suf-
ferers in America.4 It occurs more commonly 
in middle-aged and elderly women, particular-
ly following menopause at 55 to 60 years and 
being rare under 30 years with an overall prev-
alence ranging from 0,7% to 7% and a preva-
lence up to 12% to 18% for post-menopausal 
women with BMS.5,6 In recent years, the prev-
alence of BMS increased and it has become 
a common chronic orofacial pain disorder that 
reported prevalence in general population var-
ies from 0,7% to 15% 4. BMS exhibit signifi-
cant female predilection and the ratio between 
females and males varies from 3:1 to 16:1 in 
various literature studies.7
Therefore, the aim of this literature review is 
to discuss the management of burning mouth 
syndrome comprehensively in postmenopaus-
al women and may be practiced by a general 
practitioner dentist when encountering a pa-
tient with the BMS complain.
LITERATURE REVIEW
Burning Mouth Syndrome (BMS) is an idio-
pathic burning state accompanied by uncom-
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fortable pain that is generally on the tongue, 
mucous membranes and lips without the pres-
ence of medical, dental and laboratory findings 
lasting at least 4-6 months. The International 
Association of Pain studies stated that the pain 
felt lasted 4-6 months without clinical and labo-
ratory findings. 2,7–9
Most of studies suggested that majority of 
patient with BMS are middle-aged women in 
postmenopausal phase.7 The mean age of 
BMS patients is between 55 to 60 years. The 
term menopause is often used for a condition 
in which the permanent cessation of the pri-
mary function of the ovaries in humans that 
occurs especially in middle-aged women. The 
increasing population of menopausal women 
associated with other systemic disorders such 
as osteoporosis, cardiovascular disorders, cer-
vical cancer, breast cancer and other systemic 
disorders, makes us think of other problems 
that can arise in this group. Signs and symp-
toms of menopause depend on a woman’s 
lifestyle, rural-urban division, and economic 
status.10 
Available evidence suggested that BMS is a 
multifactorial disorder with physiological basis. 
Pathophysiology of BMS remains unclear. The 
etiopathogenesis of  BMS is very complex and 
in most patients who complain of burning sen-
sations have interactions with several factors 
such as local, systemic, and/ or psychogenic 
factors.6,8,9 
Local factors which could conceivably 
cause BMS in the oral cavity include dental 
treatment, candidiasis, bacterial infection, al-
lergies, TMJ-dysfunctions and dysfunctions of 
salivary glands. Different designs of denture 
problems become an important local etiologi-
cal factors. Candidiasis have been reported to 
be a common etiological factor in BMS, but it 
was a minor importance. Candida species and 
coliforms (Enterobacter and Klebsiella) have 
been found to be higher in patients with BMS. 
Local allergic reaction has been pointed out 
as an etiological factor for BMS. Some patient 
with BMS was caused by allergy of mercury 
and some patient whom wearing denture was 
allergy to substance in denture. Oral dysfunc-
tion as important local factor and parafunction, 
also dysfunction in the muscle of the stomatog-
nathic system are the most frequent causes of 
BMS and 51/150 (34%) BMS patients usually 
had inadequate saliva and suffered from oral 
dryness. The other contributing factors such as 
radiation therapy, systemic disorders and side 
effects of different drugs are important factors 
that cause a decrease in salivary flow rate.9,10,14
Systemic factors as one of etiologic factor of 
BMS can be divided into deficiencies of differ-
ent types and immunological disturbances and 
also the side-effect of drugs/therapy. Iron de-
ficiency is a common etiologic factor in BMS; 
whereas there is significant proportion of the 
patient had either B1-, B2- or B6- deficiency 
or combined deficiency of these vitamins. The 
lack of folic acid could be a causative factor 
and that in some case menopausal factor 
might be involved. Women with climacteric 
problems had oral symptoms and the most 
common symptoms are BMS. The high pro-
tein, potassium and phosphate concentrations 
in saliva in patients with idiopathic glossodynia 
might indicate that hormonal imbalance could 
cause this type of sore tongue. Nearly 50% pa-
tients with BMS were found to have some clin-
ical evidence of an immunologically mediated 
disease. 7,10,13,14
Psychological and psychosocial factors 
seem to play an important role in facial and 
orofacial pain disorders and atypical facial pain 
disorders appeared to be linked together with 
stressful life events and long-term problems. 
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Psychogenic factor have been considered as 
the most and major etiological factors in BMS 
after iron deficiency. Psychological stress in 
connection with loss due to death or separa-
tion are associated with BMS and, with the ex-
ception of local treatment, it is considered that 
treatment should be focused on the underly-
ing depression. Anxiety is more characteristic 
symptom for BMS than depression and togeth-
er with cancerphobia could be causative factor. 
Cancerphobia as a possible etiologic factor for 
idiopathic BMS.1,13,15
Based on a related etiology, BMS can be di-
vided into primary and secondary types, which 
the primary type includes idiopathic, non-neu-
ropathic, while the secondary type (which is 
now more commonly called burning mouth 
sensation) is more related to organic or ther-
apeutic factors. Burning mouth syndrome has 
been divided into three subtypes based on the 
daily variation of the symptoms in table 1.7,8
In establishing a BMS diagnosis, it requires 
careful analysis of the symptoms of each indi-
vidual. The main symptoms of burning pain in 
the oral cavity does not subside for at least 4-6 
months, and continue to occur throughout the 
day. In addition, the burning sensation does 
not interfere with sleep and does not worsen 
but can be reduced by eating or drinking. Other 
oral symptoms such as dysgeusia and xerosto-
mia and the presence of sensory / chemo-sen-
sory anomalies, mood change, and specific 
disorders of the patient’s personality traits can 
also help identify BMS. Clinical diagnosis can 
be obtained based on a patient’s history of sys-
temic and dental diseases and careful analysis 
of the diagnosis based on physical and labora-
tory examinations.6
DISCUSSION
Since BMS is a disorder caused by multifac-
torial factors, the therapy must be comprehen-
sive including hormone replacement therapy, 
systemically therapy, and topical medication 
as well as reassurance as the stress manage-
ment.6
1. Hormone Replacement Therapy (HRT)
Burning mouth sensation is often experi-
enced in climacteric women. Previous study 
examined the relationship between oral cav-
ity discomfort in postmenopausal women by 
149 people and found that the prevalence of 
women with oral discomfort was higher (43%) 
Table 1. Subtypes of burning mouth syndrome (BMS).1,2,7,8
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occurred in perimenopausal and postmeno-
pausal women compared to premenopausal 
women (6 %). These results also showed an 
association between oral cavity discomfort and 
psychological symptoms in postmenopausal 
women. Two thirds of women who experience 
oral discomfort do not have clinical symptoms 
and feel reduced after Hormone Replacement 
Therapy (HRT). Current data shows support for 
the use of hormone therapy (HT) in perimeno-
pausal and postmenopausal women when the 
benefits and risks of this therapy are balanced 
for each individual woman. This statement re-
views the effects of estrogen therapy (ET) and 
estrogen-progesterone therapy (EPT) on sev-
eral aspects of women’s health and can iden-
tify greater levels of safety associated with es-
trogen therapy.6,26,27 
Table 2. Drugs (systemically & topical) as the treatment of Burning Mouth Syndrome (BMS).
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2. Systemically Therapy
Previous research examined patients who 
had BMS were given Olanzapine initially 2.5 
mg / day and increased 5.0 mg / day the fol-
lowing week. There was a decrease in BMS 
symptoms in patients taking Olanzapine in the 
first week. Olanzapine is a strong antagonist 
against a number of neuronal receptors, such 
as dopamine, norepinephrine, and serotonin. 
The efficacy of Olanzapine in BMS therapy is 
because it partly blocks the subset of dopa-
mine receptors.3 Heckmann research revealed 
that clonazepam was effective in reducing pain 
experienced by BMS patients at the same 
time that clonazepam was well tolerated by 
all subjects. Clonazepam has no major effect 
on psychological changes and clonazepam 
has little impact on the patient’s psychological 
status. The effect of clonazepam is explained 
by agonistic action on the GABA-inhibitor re-
ceptors which are also in the taste line.21 Ro-
driguez-Cerdeira research revealed that ther-
apy with amisulpride has a good effect and 
tolerance on short-term BMS treatment. This is 
related to good adherence in the first week of 
treatment and a brief response to latency, es-
pecially useful in the initial treatment of BMS.24 
Stuginski-Barbosa et al.(2008)18 revealed that 
pramipexol was given 0.125 mg at night after 
1 week the patient experienced a development 
of 20% (decrease from seven to five) based 
on Visual Analogical Scale (VAS). The dose is 
then slowly increased to 0.75 mg at night, in 
the fourth week the complaint disappears. But 
after the medication was stopped, the symp-
toms returned on the sixth day.18 Lopez-D’ales-
sandro et al.in 2011 stated the combination of 
alpha lipoic acid and Gabapentine has a good 
response to the burning sensation which is 
about 70% of people with BMS. Combinations 
of drugs that have different levels of action in 
the nociceptive system are very useful in treat-
ing this disorder.22
3. Topical Therapy
Capsaicin acts on sensory afferent neu-
rons, and topical capsaicin can be used as a 
desensitization agent or analgesic which plays 
a role in the treatment of burning oral muco-
sa. However, it’s hard to accept because of 
its spicy taste which makes it uncomfortable 
when used. Furthermore, there can be an in-
creased sensation of burning at the beginning 
of treatment.20 Clonazepam 1 mg tablets are 
sucked by the patient then hold their saliva 
near the main location in the mouth without 
swallowing for 3 minutes and then discarded. 
This method is repeated three times a day for 
14 days. There can be a greater reduction in 
pain scores in patients with clonazepam than 
in placebo-treated patients and suggest that 
the action of this drug is related to peripheral 
nervous system dysfunction in patients with 
BMS and the presence of GABA receptors in 
peripheral tissues.17,28 Aloe vera belongs to 
the Liliacea family. Topical Aloe vera has been 
shown to promote healing processes in the 
treatment of burns, psoriasis, and oral lichen 
planus. Lopez-Jornet et al. in 2013 found that 
topical application 0.5 ml of Aloe vera gel at 
70% to the tongue pain area three times a day 
combined with a tongue protector (transparent, 
low density polyethylene sheath covering the 
tongue from the third posterior end) is effec-
tive for reducing burning sensation and tongue 
pain.19
4. Vitamin and Zinc Supplement 
Cho et al. in 2010, stated that nutritional de-
ficiencies are involved in the cause of BMS in 
one third of people with BMS, including defi-
ciencies in vitamins B1, B2, B6, B12, folic acid 
and zinc. Several randomized controlled trials 
have evaluated the effectiveness of vitamin re-
placement in treating patients with BMS. For 
example, 40% of patients with BMS, compared 
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with 7.5% of the control group, found deficien-
cies in vitamin B1, B2, and ⁄ or B6, and this 
vitamin replacement therapy resolved symp-
toms in 30% of patients who were deficient. 
These findings suggest that empirical replace-
ment with vitamin B1 (300 mg, once a day) 
and vitamin B6 (50 mg, three times a day) for 
4 weeks may be effective in treating patients 
with BMS. Patients with zinc deficiency are 
treated with zinc supplements (14.1 mg / day) 
for 6 months. This finding suggests that zinc 
supplement therapy in BMS patients who have 
zinc deficiency is effective in reducing symp-
toms of burning in the oral cavity.23,25
5. Reassurance
Brailo et al. in 2016 stated that if BMS is 
a condition whose treatment has not been ef-
fective so that it can cause emotional condi-
tions such as depression, anxiety, pain-related 
catastrophizing.29 Catastrophizing is related to 
anxiety that is conceptualized as a negative 
cognitive-affective response to pain which is a 
tendency to enlarge or exaggerate the value of 
the threat of pain sensation. This can be cou-
pled with an inability to distract from pain.30,31 
There is a study by Matsuoko, et al. in 2010 
stated that reassurance has a good effect on 
pain perception in BMS patients.32 Reassur-
ance can be achieved by providing objec-
tive information about conditions that reduce 
pain-related catastrophizing and increase the 
quality of life in people with BMS. Changing 
and eliminating a negative mindset and behav-
ior is a very important factor in the treatment of 
chronic pain regardless of the causes and ba-
sic forms of cognitive behavioral therapy (CBT) 
and patients with BMS show a significant re-
duction in pain intensity and anxiety after CBT 
for 6 months. In addition to pain-related cat-
astrophizing, informative intervention has a 
positive impact in improving quality of life. Im-
provement of quality life occurs after patients 
with BMS undergo CBT. This study emphasiz-
es the importance of communication between 
dentists and patients. This is very relevant to 
the treatment of chronic pain such as BMS.29
CONCLUSION
Proper management of the BMS involves 
the combination of pharmacologic treatment 
such as systemic and topical therapy, as well 
as reassurance for stress management is an 
important thing.
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